Dr. Reddy’s Laboratories launches Olanzapine Tablets

India Infoline News Service | Mumbai | April 25, 2012 08:36 IST

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Laboratories announced today that it has launched Olanzapine Tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg), a bioequivalent generic version of ZYPREXA Tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Olanzapine Tablets.

Dr. Reddy’s Olanzapine Tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the U.S. on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries Ltd.

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths are available in 30 and 500 count bottles.

BSE 2,968.25 [43.85] ([1.46]%)
NSE 2,959.35 [52.45] ([1.74]%)

***Note: This is a NSE Chart